NeoCore Technology Co

NeoCore Technology Co Gross Margin

The Gross Margin of NeoCore Technology Co (4131.TWO) as of Nov 11, 2026 is 5.35 %. In the previous year, Gross Margin was -14.04 % — a change of -138.11% (higher).

Gross Margin

5.35 %

YoY

-138.11%

Last updated:

Gross Margin of NeoCore Technology Co is 2024 5.35 % . Gross Margin of NeoCore Technology Co was 2023 -14.04 % . It decreases by -138.11% higher compared to the previous year.

NeoCore Technology Co's gross margin stands at 5.3%, down from 20.4% several years earlier.

The NeoCore Technology Co Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2017
48.95 TWD
Jan 1, 2018
24.62 TWD
Jan 1, 2019
39.87 TWD
Jan 1, 2020
20.38 TWD
Jan 1, 2021
21.82 TWD
Jan 1, 2022
13.25 TWD
Jan 1, 2023
-14.04 TWD
Jan 1, 2024
5.35 TWD
The NeoCore Technology Co Gross Margin history
YEARGross MarginYoY
5.35 %-138.11%
-14.04 %-205.97%
13.25 %-39.29%
21.82 %+7.04%
20.38 %-48.88%
39.87 %+61.93%
24.62 %-49.70%
48.95 %-9.99%
54.38 %+0.33%
54.20 %-15.08%
63.83 %+30,183.08%
0.21 %-49.25%
0.42 %-37.57%
0.67 %+1.27%
0.66 %-5.48%
0.70 %-16.66%
0.83 %+16.61%
0.72 %+22.94%
0.58 %-547.69%
-0.13 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NeoCore Technology Co Stock analysis

What does NeoCore Technology Co do? NeoCore Technology Co Ltd generates revenue through the sale of biochips and related biotechnology products. The company develops and manufactures DNA/RNA sample preparation kits, polymerase chain reaction kits, rapid hybridization equipment, biochips, testing reagents, biological preparations, nucleic acid sequencing detection systems, biotechnology control hardware and software, and biomedical materials. These products are primarily sold within Taiwan and exported to Asian and European markets. The company's domestic sales focus on the Taiwanese market while international exports target Asian and European customers. DR. Chip Biotechnology, Inc. operates as the parent company for NeoCore Technology Co Ltd, managing the research, development, manufacturing, and sales of biochips. The business model relies on direct sales of its comprehensive product portfolio to domestic and international clients in the biotechnology sector. The company's product range serves both laboratory and commercial applications within the biotechnology industry. NeoCore Technology Co Ltd's revenue streams include the sale of biochips, DNA/RNA sample preparation kits, polymerase chain reaction kits, and related components. The company's export focus on Asia and Europe drives international sales, while domestic sales in Taiwan form a significant portion of its business. The company's product offerings cater to the needs of biotechnology laboratories and commercial entities requiring advanced biotech solutions. NeoCore Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NeoCore Technology Co stock

Gross Margin of NeoCore Technology Co is 5.35 % in 2024.

Gross Margin of NeoCore Technology Co changed from -14.04 % to 5.35 %, representing a -138.11% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin NeoCore Technology Co since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's NeoCore Technology Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — NeoCore Technology Co

All Key Metrics — NeoCore Technology Co